Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | CCR8 | P51685 | 4/20 | 0.62 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562348 | 0.87 | LTA4H (0.55) | SIGMAR1FAAH | |
| SCHEMBL6528757 | 0.84 | KDM4E (0.64) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL6505051 | 0.84 | CCR8 (0.54) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL6504157 | 0.84 | CCR8 (0.66) | ALDH1A1KDM4ETDP1CCR8SIGMAR1 | |
| SCHEMBL6943757 | 0.84 | SIGMAR1 (0.68) | ALDH1A1KDM4EGAASIGMAR1 | |
| SCHEMBL6499571 | 0.83 | ALDH1A1 (0.75) | ALDH1A1KDM4ETDP1HPGDHTT | |
| Hydrochloric Acid SCHEMBL11535920 | 0.83 | SIGMAR1 (0.67) | ALDH1A1KDM4EGAASIGMAR1 | |
| SCHEMBL6496864 | 0.82 | ALDH1A1 (0.73) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL15243730 | 0.81 | MBTD1 (0.62) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL6527830 | 0.81 | CCR8 (0.61) | ALDH1A1KDM4ETDP1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| CN-1143858-C | 6, 9-disubstituted 2- [ trans- (aminocyclohexyl) amino ] purines, compositions and uses thereof | ������ҩ������˾ | 2004-03-31 | — | — | CN | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | ALDH1A1 2147/4885KDM4E 990/4885TDP1 210/4885 |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | ALDH1A1 1071/4885KDM4E 4617/4885TDP1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.